ストックスクリーナーアプリを入手
176.80
1.28%
-2.30
プレマーケット:
177.82
1.02
+0.58%
前日終値:
$179.10
開ける：
$177.7
24時間の取引高:
8.08M
Relative Volume:
1.19
時価総額：
$312.76B
収益：
$56.33B
当期純損益:
$4.28B
株価収益率:
73.67
EPS:
2.4
ネットキャッシュフロー:
$17.83B
1週間 パフォーマンス:
+0.64%
1か月 パフォーマンス:
-16.51%
6か月 パフォーマンス:
-7.85%
1年 パフォーマンス:
+9.36%
1日の値動き範囲:
$176.31
$180.50
1週間の範囲:
$164.39
$180.60
52週間の値動き範囲:
$153.58
$218.66
Abbvie Inc Stock (ABBV) Company Profile
ABBV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
176.80 | 312.76B | 56.33B | 4.28B | 17.83B | 2.40 |
|
LLY
Lilly Eli Co
|
757.18 | 680.08B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
153.62 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
64.49 | 286.27B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
109.93 | 217.12B | 51.72B | 11.94B | 13.81B | 5.88 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-12-05 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-04 | アップグレード | Argus | Hold → Buy |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-06-05 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-05-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-01-29 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-12-11 | アップグレード | Goldman | Neutral → Buy |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-10-30 | アップグレード | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-07-25 | 開始されました | William Blair | Mkt Perform |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-05 | ダウングレード | Argus | Buy → Hold |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2023-02-22 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-11-08 | ダウングレード | Societe Generale | Buy → Hold |
| 2022-08-01 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Underperform |
| 2022-05-06 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2022-02-28 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-03 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-03 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-03 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-03 | 繰り返されました | Goldman | Neutral |
| 2022-01-13 | 開始されました | Redburn | Buy |
| 2022-01-12 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-12-09 | 再開されました | Wells Fargo | Overweight |
| 2021-11-23 | アップグレード | Societe Generale | Hold → Buy |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2020-11-10 | 再開されました | Bernstein | Outperform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-23 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | アップグレード | Argus | Hold → Buy |
| 2020-05-18 | 再開されました | BofA/Merrill | Neutral |
| 2020-05-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 再開されました | Morgan Stanley | Overweight |
| 2020-04-20 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | ダウングレード | Societe Generale | Buy → Hold |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 繰り返されました | Cowen | Outperform |
| 2019-09-26 | アップグレード | Citigroup | Neutral → Buy |
| 2019-08-20 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 開始されました | Goldman | Neutral |
| 2019-04-29 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
すべてを表示
Abbvie Inc (ABBV) 最新ニュース
Interleukin Inhibitors Market Is Booming Worldwide | AbbVie - openPR.com
Drug company files suit against South Dakota over new 340B law - South Dakota Public Broadcasting
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks - Yahoo Finance
The Zacks Analyst Blog AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment - TradingView
Top Research Reports for AbbVie, TJX & Charles Schwab - Yahoo Finance
AbbVie Asks Court to Extend Venclexta Cancer-Drug Patent’s Life - Bloomberg Law News
AbbVie Options Trading: A Deep Dive into Market Sentiment - Nasdaq
AbbVie Inc. (ABBV): One of the High Growth Forever Dividend Stocks to Invest In - Yahoo Finance
Drugmaker sues SD over law preserving broad access to discounts for hospitals, pharmacies - Argus Leader
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
AbbVie and Sandoz agree to drop court spat over Rinvoq patents - Endpoints News
ABBV vs. MRK: Which Drug Giant is a Better Buy Now? - Yahoo Finance
Arthralgia Market to Reach New Heights in Growth by 2032, - openPR.com
The Zacks Analyst Blog Merck And AbbVie - Barchart.com
Meta, TJX, Taiwan Semiconductor Manufacturing And A Health Care Stock: CNBC's 'Final Trades' - Benzinga
Earnings Preview: What to Expect From AbbVie's Report - Nasdaq
Earnings Preview: What To Expect From AbbVie's Report - Barchart.com
10 High Growth Forever Dividend Stocks To Invest In - Insider Monkey
The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis - TradingView
Is AbbVie Inc. (ABBV) the Best Stock for 15 Years? - Yahoo Finance
Skin Boosters Market to Witness Stunning Growth with AbbVie, Medytox, ExoCoBio - openPR.com
AbbVie (ABBV) Faces Volatility Despite Positive Earnings in Q1 2 - GuruFocus
AbbVie, Sandoz Settle Patent Fight Over Rinvoq Generics - Law360
Multiple Myeloma Pipeline 2025: Latest FDA Approvals, Clinical - openPR.com
AbbVie Unusual Options Activity - Benzinga
AbbVie (NYSE:ABBV) Shares Down 5.6%Should You Sell? - MarketBeat
AbbVie Aesthetics Line Faces Potential Risk in Current Macro Environment, UBS Says - MarketScreener
AbbVie Brings New Suits Against State Pharmacy Contract Laws - Bloomberg Law News
Pharma Stock Roundup: EU Nod to Expanded Use of ABBV, AZN Drugs & More - TradingView
Ex-Dividend Reminder: Buckle, AbbVie and Abbott Laboratories - Nasdaq
Here’s Why Clearbridge Growth Strategy Sold AbbVie (ABBV) - Insider Monkey
ABBV Stock Upgraded to Buy Amid Valuation Insights - GuruFocus
AbbVie Files Lawsuits to Block Drug Pricing Laws in North Dakota and South Dakota - USA Herald
Personalized Medicine Market Forecast Report and Company Analysis 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La RocheResearchAndMarkets.com | FinancialContent - FinancialContent
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies - Benzinga
AbbVie Wants ND, SD Drug Pricing Laws Blocked - Law360
AbbVie Inc (ABBV) Trading Down 4.25% on Apr 9 - GuruFocus
Male Hypogonadism Market Forecast Report and Company Analysis 2025-2034 Featuring AbbVie, Bayer, Eli Lilly, Endo, Ferring, Perrigo, Pfizer, Sanofi, Teva, and Viatris - GlobeNewswire Inc.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know - Yahoo Finance
AbbVie Stock Up 9.2% After Key Signal - Benzinga
Novo Nordisk, AbbVie Stocks Slide After Trump Vows Pharma Tariffs - WSJ
AbbVie: Thriving Beyond Humira's Patent Cliff (Upgrade) (NYSE:ABBV) - Seeking Alpha
AbbVie wins EC nod for new Rinvoq indication - The Pharma Letter
Morgan Stanley Adjusts Price Target on AbbVie to $241 From $239, Keeps Overweight Rating - MarketScreener
Reproductive Hormone Market Is Booming Worldwide 2025-2032 | AbbVie Inc., Allergan plc, Pfizer Inc. - openPR.com
AbbVie (ABBV): A Top Dividend Stock to Weather Economic Storms - GuruFocus
AbbVie's Rinvoq (ABBV) Receives EU Approval for Giant Cell Arteritis - GuruFocus
Immunology Market Growth in Future Scope 2025-2032 | AbbVie - openPR.com
AbbVie’s upadacitinib gains EU marketing authorisation for GCA - Yahoo
AbbVie secures EU approval for Rinvoq to treat GCA in adults - World Pharmaceutical Frontiers
AbbVie (ABBV) Gains EU Approval for RINVOQ in Treating Giant Cel - GuruFocus
Abbvie Inc (ABBV) 財務データ
収益
当期純利益
現金流量
EPS
2.38%
0.43%
大文字化:
|
ボリューム (24 時間):